Valence Logo
Popular
Login
Loading data for ERAS — first visit, this takes a few seconds.

Add to Watchlist

Erasca Inc.

NasdaqGS: ERAS · Real-Time Price · USD
18.10
-0.18 (-0.98%)
At close: Aug 18, 2026, 8:00 PM
18.10
+0.00%
Pre-market: 5:48 AM

Erasca Inc. (ERAS) Stock Price, Analysis & Data

-0.98%

No data available

Bid13.27
Market Cap6.33B
Revenue (ttm)n/a
Net Income (ttm)-287.22M
Beta0.65
EPS (ttm)-0.95
PE Ratio (ttm)n/a
Forward PE-31.11
P/B (ttm)15.63
P/S (ttm)n/a
Earnings DateNov 11, 2026
Ask23
Volume1,830,092
Avg. Volume (20D)4,923,824
Open18.19
Previous Close18.28
Day's Range17.85 - 18.72
52-Week Range1.33 - 24.28
Analystn/a
Price Targetn/a
Dividendsn/a
Ex-Dividend Daten/a

About ERAS

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 ...

[Read more]
Industry Biotechnology
Sector Healthcare
IPO Date Jul 16, 2021
Employees 103
Stock Exchange NasdaqGS
Ticker Symbol ERAS
Website https://www.erasca.com
Full Company Profile

Financial Performance

In 2025, Erasca's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -124.55M, a decrease of -22.95%.

Financial Statements

Earnings Surprise

Erasca has released their quarterly earnings on Aug 11, 2026:
  • Revenue of $0 misses estimates by $0, with NaN% YoY growth.
  • EPS of -0.14 misses estimates by -0.03, with -16.67% YoY decline.

    • Next Earnings Release

    Erasca Inc. is scheduled to release its earnings on Nov 11, 2026, during market hours.
    Analysts project revenue of ... Upgrade
    news image

    1 month ago · Simply Wall St.

    Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns

    Erasca stock has delivered an extremely large 1 year gain, yet its valuation checks lean expensive, so the current price is testing how much optimism investors are willing to embed into the story this...

    news image

    1 month ago · Simply Wall St.

    Erasca (ERAS) Trial Update Draws Fresh Focus, Is The Valuation Already Full?

    Erasca (ERAS) has been in focus after updated preliminary Phase 1 data for ERAS-0015 in RAS-mutant solid tumors, including pancreatic cancer, coincided with a sizeable follow-on equity offering and a ...

    news image

    1 month ago · Simply Wall St.

    Erasca (ERAS) Is Up 6.2% After Advancing ERAS-0015 Toward Registration Trials In RAS Cancers

    Erasca recently reported updated preliminary Phase 1 data for its oral pan-RAS molecular glue ERAS-0015, showing encouraging responses and a generally well-tolerated safety profile in RAS-mutant solid...

    news image

    1 month ago · Insider Monkey

    Erasca (ERAS) Surges 8.9% on Encouraging Cancer Trial Results

    Erasca rallied by 8.94 percent on Tuesday to close at $19.50 apiece, as investor sentiment was boosted by the strong clinical trial results of its treatment candidate for RAS-mutant solid tumors, stre...

    news image

    1 month ago · Barrons.com

    Robinhood and 4 More Stocks That Were Just Added to This Firm’s ‘Top Picks’ List

    Robinhood Markets is added as a top stock for July. Micron and Oracle are among Mizuho Securities’ top picks for the month.

    Page 1 of 2